Amino Acid

    L-Phenylalanine

    L-Phenylalanine

    TL;DR

    L-phenylalanine is the essential precursor to tyrosine, dopamine and noradrenaline. Its best-supported use is in medically supervised phototherapy for vitiligo; mood claims rest on old, low-quality trials.

    Ideal For

    • People undergoing supervised UVA phototherapy for vitiligo

    Avoid If

    • You have phenylketonuria — absolute contraindication
    • You take an MAO inhibitor
    • You have uncontrolled high blood pressure
    • You have a history of melanoma or significant photosensitivity

    Frequently Asked Questions

    Overview

    L-phenylalanine is essential and abundant in dietary protein. Hydroxylated to tyrosine, it feeds the catecholamine pathway, which is the mechanistic story behind mood and focus marketing. The evidence for that use is weak: the antidepressant trials date from the 1970s and 1980s, are small, mostly uncontrolled, and would not pass modern review. Where it has held up better is vitiligo, where oral L-phenylalanine combined with UVA phototherapy produced repigmentation in several controlled studies — a niche but real indication, and one that requires dermatological supervision. DL-phenylalanine, the racemic mix, is separately promoted for chronic pain on the theory that the D-isomer inhibits enkephalin breakdown; human trials for this are small and conflicting. The absolute contraindication is phenylketonuria, where the enzyme converting phenylalanine to tyrosine is deficient and accumulation causes neurological damage — this is why aspartame carries a PKU warning. For people wanting a catecholamine precursor without the PKU issue and with more trial data, L-tyrosine is the better-studied option.

    How It Works

    • Hydroxylated by phenylalanine hydroxylase to tyrosine, the direct precursor to L-DOPA and dopamine
    • Feeds noradrenaline and adrenaline synthesis downstream of dopamine
    • Stimulates melanocyte activity when combined with UVA exposure, the basis of the vitiligo protocol
    • D-isomer may inhibit enkephalinase, prolonging endogenous opioid signalling

    Benefits & Outcomes

    No linked outcomes yet. Research is ongoing.

    Supporting Research
    5 studies

    Key European guidelines for the diagnosis and management of patients with phenylketonuria

    Score: 9/10
    2017
    systematic_review

    van Spronsen FJ, van Wegberg AM, Ahring K

    Phenylalanine intake must be strictly restricted lifelong in phenylketonuria because elevated blood phenylalanine is neurotoxic.

    View source

    L-phenylalanine and UVA irradiation in the treatment of vitiligo

    Score: 5/10
    1994
    rct
    n=32

    Siddiqui AH, Stolk LM, Bhaggoe R

    L-phenylalanine with UVA produced significantly greater facial repigmentation than UVA alone.

    View source

    Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience

    Score: 4/10
    1999
    observational
    n=149

    Camacho F, Mazuecos J

    Oral and topical phenylalanine with light exposure produced repigmentation in most vitiligo patients over six years of practice.

    View source

    Phenylalanine and UVA light for the treatment of vitiligo

    Score: 3/10
    1985
    observational
    n=149

    Cormane RH, Siddiqui AH, Westerhof W

    Phenylalanine combined with UVA exposure produced repigmentation in a majority of treated vitiligo patients.

    View source

    DL-phenylalanine versus imipramine: a double-blind controlled study

    Score: 3/10
    1979
    rct
    n=40

    Beckmann H, Athen D, Olteanu M

    DL-phenylalanine produced antidepressant effects comparable with imipramine in a small 1970s inpatient trial.

    View source

    Safety Information

    Potential Side Effects

    Headache, anxiety, insomnia, nausea and heartburn. Blood pressure can rise, particularly in combination with stimulants.

    Contraindications

    Phenylketonuria, MAOI use, uncontrolled hypertension, pregnancy.

    Drug Interactions

    • MAO inhibitors — hypertensive crisis risk
    • Levodopa — competes for the same transporter and can reduce efficacy
    • Antipsychotics — theoretical risk of worsening tardive dyskinesia

    Pregnancy & Breastfeeding

    Pregnancy: insufficient_data

    Breastfeeding: insufficient_data

    Dosage Guidelines

    Dosage Used in Studies

    Consult healthcare provider

    Forms Compared

    Food & Timing

    On an empty stomach, away from other amino acids that compete for the same transporter.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.